Scarica l'app Stockscreener
15.43
5.69%
0.84
Precedente Chiudi:
$14.59
Aprire:
$14.67
Volume 24 ore:
78,137
Relative Volume:
0.17
Capitalizzazione di mercato:
$413.79M
Reddito:
$31.38M
Utile/perdita netta:
$-6.69M
Rapporto P/E:
-59.35
EPS:
-0.26
Flusso di cassa netto:
$-1.84M
1 W Prestazione:
+11.02%
1M Prestazione:
+14.14%
6M Prestazione:
-5.05%
1 anno Prestazione:
+334.37%
Intervallo 1D:
$14.52
$15.47
Intervallo di 1 settimana:
$13.85
$15.47
Portata 52W:
$3.2519
$21.48
Eton Pharmaceuticals Inc Stock (ETON) Company Profile
Nome
Eton Pharmaceuticals Inc
Settore
Telefono
(847) 787-7361
Indirizzo
21925 W. FIELD PARKWAY, DEER PARK, IL
Confronta ETON con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ETON
Eton Pharmaceuticals Inc
|
15.43 | 386.98M | 31.38M | -6.69M | -1.84M | -0.26 |
|
ZTS
Zoetis Inc
|
152.63 | 68.05B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.77 | 46.58B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.745 | 43.71B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.50 | 18.40B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
305.38 | 13.23B | 2.99B | 1.21B | 1.13B | 25.06 |
Eton Pharmaceuticals Inc Stock (ETON) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-23 | Reiterato | H.C. Wainwright | Buy |
| 2025-01-10 | Iniziato | B. Riley Securities | Buy |
| 2025-01-06 | Reiterato | H.C. Wainwright | Buy |
| 2024-09-04 | Ripresa | H.C. Wainwright | Buy |
| 2024-05-06 | Iniziato | Craig Hallum | Buy |
| 2021-10-14 | Ripresa | B. Riley Securities | Buy |
| 2021-01-04 | Reiterato | H.C. Wainwright | Buy |
| 2019-09-20 | Iniziato | B. Riley FBR | Buy |
| 2019-06-10 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Eton Pharmaceuticals Inc Borsa (ETON) Ultime notizie
What analysts say about Eton Pharmaceuticals Inc. stockLightning-fast capital gains - jammulinksnews.com
Eton Pharmaceuticals Inc. Stock Analysis and ForecastBreakthrough financial growth - jammulinksnews.com
Is Eton Pharmaceuticals Inc. a good long term investmentRapid return acceleration - jammulinksnews.com
What drives Eton Pharmaceuticals Inc. stock priceExtraordinary profit generation - jammulinksnews.com
What makes Eton Pharmaceuticals Inc. stock price move sharplyHigh Yield Opportunities - Newser
Top Growth Companies With Insider Stakes July 2025 - simplywall.st
B. Riley Analysts Lift Earnings Estimates for ETON - Defense World
B. Riley Boosts Earnings Estimates for Eton Pharmaceuticals - Defense World
ETON’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com
How Eton Pharmaceuticals Inc. stock performs during market volatilityLow Risk Profit Ideas - Newser
Why Eton Pharmaceuticals Inc. stock attracts strong analyst attentionCapital Preservation Investment Ideas - Newser
Eton Pharmaceuticals: A Contrarian Play on Delayed Catalysts and Long-Term Value - AInvest
Eton Pharma Near Term Catalysts Vanish (NASDAQ:ETON) - Seeking Alpha
(ETON) Trading Report - news.stocktradersdaily.com
Institutional investors are Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) biggest bettors and were rewarded after last week's US$48m market cap gain - simplywall.st
FDA accepts Eton’s NDA for ET-600 desmopressin oral solution By Investing.com - Investing.com South Africa
Eton Pharmaceuticals Announces Fda Acceptance of New Drug Application for Et-600 (Desmopressin Oral Solution) - MarketScreener
Eton stock gains as new therapy gets FDA review (ETON) - Seeking Alpha
Eton Pharmaceuticals announces FDA acceptance of new drug application for ET-600 - MarketScreener
FDA accepts Eton’s NDA for ET-600 desmopressin oral solution - Investing.com
Eton Pharmaceuticals Announces FDA Acceptance of NDA for ET-600 with Target Action Date of February 25, 2026 - Quiver Quantitative
Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-600 (Desmopressin Oral Solution) - The Manila Times
Eton's New Pediatric Drug Solution Advances Toward FDA Approval, Targeting $1B Market Opportunity - Stock Titan
Eton Pharmaceuticals to join Russell indexes - MSN
Eton Pharmaceuticals (ETON) to Join Russell 3000 and 2000 Indexes | ETON Stock News - GuruFocus
Eton Pharmaceuticals Announces Addition to Russell 2000® and Russell 3000® Indexes - The Manila Times
ETON switches auditor: Crowe LLP out, Grant Thornton in – no disputes | ETON SEC FilingForm 8-K - Stock Titan
Opaleye Management Inc. Increases Stake in Eton Pharmaceuticals Inc. - GuruFocus
Insiders Back These 3 High Growth Companies - Yahoo Finance
Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) 25% Cheaper Price Remains In Tune With Revenues - simplywall.st
Bank of America Corp DE Boosts Stake in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) - Defense World
Insider Sell: David Krempa Sells 34,000 Shares of Eton Pharmaceu - GuruFocus
Insider Sell: David Krempa Sells 34,000 Shares of Eton Pharmaceuticals Inc (ETON) - GuruFocus
Eton Pharma wins FDA nod for oral hydrocortisone solution - MSN
Eton Pharmaceuticals, Inc. (ETON) Launches Game-Changer for Adrenal Insufficiency - MSN
Major Shareholder Increases Stake in Eton Pharmaceuticals! - TipRanks
Eton Pharmaceuticals Holds Annual Stockholders Meeting - TipRanks
Trend Tracker for (ETON) - news.stocktradersdaily.com
B. Riley Forecasts Higher Earnings for Eton Pharmaceuticals - Defense World
Eton Pharmaceuticals: Rapid Revenue Growth And Pipeline Catalysts Point To More Upside - Seeking Alpha
Insider Sell: Sean Brynjelsen Sells 210,000 Shares of Eton Pharm - GuruFocus
Eton Pharmaceuticals Inc Azioni (ETON) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Eton Pharmaceuticals Inc Azioni (ETON) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Krempa David | Chief Business Officer |
Jun 16 '25 |
Sale |
14.73 |
10,223 |
150,585 |
612,646 |
| Krempa David | Chief Business Officer |
Jun 13 '25 |
Sale |
14.77 |
6,800 |
100,436 |
622,869 |
| Opaleye Management Inc. | 10% Owner |
Jun 10 '25 |
Buy |
15.82 |
7,930 |
125,484 |
2,770,000 |
1.18%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):